Abstract: Etanercept is approved for the treatment of moderate to severe plaque psoriasis at a dose of 50 mg twice weekly for 3 months followed by a maintenance dosage of 50 mg weekly thereafter. Clinical studies have shown excellent effi cacy, favorable benefi t to side-effects ratio, and safe long-term usage. Extensive information on safety is available as etanercept has been used for many years for other indications such as rheumatoid arthritis and psoriatic arthritis and is the fi rst of the tumor necrosis factor antagonists to gain approval in psoriasis.
Introduction
Etanercept (Enbrel ® ; Amgen-Wyeth) is a fully human tumor necrosis factor (TNF) receptor that reduces the infl ammatory response by inhibiting interactions between TNF and cell-surface TNF receptors. Currently three TNF antagonists (adalimumab, infl iximab and etanercept) are approved by the US Federal Drug and Administration (FDA) for the treatment of plaque psoriasis. Adalimumab and etanercept are indicated in the treatment of moderate to severe plaque psoriasis, whereas infl iximab is indicated for severe plaque psoriasis. Adalimumab and infl iximab are monoclonal antibodies, while etanercept is a soluble receptor fusion protein. Etanercept is also FDA approved for rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis (JIA), and ankylosing spondylitis (AS).
Etanercept is an important therapeutic option in patients with moderate to severe plaque psoriasis. Studies have found it to have a high effi cacy, favorable benefi t to side-effects ratio, and safe long-term usage compared to other systemic treatments for psoriasis such as methotrexate, cycloporine, and PUVA. Effective treatment of psoriasis is needed because of the associated morbidity of psoriasis. Quality-of-life studies in patients with psoriasis attest to its signifi cant impact on day to day activities and effect on personal relationships. 1, 2 Patients with psoriasis have increased disease-related inability to work, 3 and face signifi cant discrimination with resulting fi nancial diffi culties and depression. 4 Psoriasis has also been associated with several comorbid conditions including obesity and cardiovascular disease. 2, 5, 6 These data have prompted an awareness and interest in more aggressive management of psoriasis including biologic agents.
Mechanism of action
Etanercept is a fully soluble, human dimeric fusion protein with a molecular weight of 150 kDa. It consists of two extracellular ligand-binding domains of the human 75 kDa TNF receptor linked to the Fc portion of human immunoglobulin G1 (IgG1) by three disulfi de bonds. The protein is produced using recombinant DNA technology in a mammalian Chinese hamster ovarian cell line and consists of 934 amino acids. 7, 8 Despite the presence of an Fc region, etanercept does not promote complement-mediated cell lysis in vitro as opposed to the monoclonal antibodies that do exhibit this in vitro. 9 Nguyen and Koo Etanercept acts as a competitive inhibitor of TNF, a naturally occurring proinfl ammatory cytokine produced by many different cell types including activated T cells, fi broblasts, adipocytes, and keratinocytes. TNF acts as a key mediator of infl ammatory processes in the pathogenesis of psoriasis and psoriatic arthritis.
Etanercept inhibits the activity of TNF by competitively binding it, thus antagonizing interactions with TNF receptors on cell surface, and preventing activation of the infl ammatory cascade. It is unique among TNF blocking biologic agents for psoriasis in that it mimics the activity of naturally occurring soluble TNF receptors, and prevents binding of free, soluble, non-membrane-bound TNF. There are two distinct receptors for naturally-occurring TNF: p55, also known as TNF-β or lymphotoxin, and p75, which is TNF-α. Biological activity of TNF is modulated through these receptors. [10] [11] [12] Elevated levels of TNF-α have been found in fl uid from patients with psoriatic arthritis, psoriatic skin lesions, and serum of patients with plaque psoriasis. 13 TNF-α stimulates the production of chemokines and the expression of adhesion molecules by keratinocytes and vascular endothelial cells. The release of these signals cause recruitment of additional infl ammatory cells into the plaque, amplifying the infl ammatory process within psoriatic plaques.
14 Treatment with etanercept has been shown to reduce several markers of infl ammation within biopsied plaques. 15 Moreover, serum and lesional TNF-α levels directly correlate with the severity of psoriasis, as measured by the psoriasis area and severity index (PASI) score. 16, 17 Additionally, the dimeric nature of etanercept protein allows the binding of TNF-α at an affi nity that is 50 to 1000 times greater than in naturally occurring TNF-α receptors. 8 Etanercept may also weakly interact with the TNF-β receptor, which acts on B-cells, T-cells, NK-cells and lymphoid architecture to stimulate immunoreactivity. 10, 11 TNF-β inhibition has been shown to be effective in moderating the symptoms of psoriasis. However, onercept, a human recombinant soluble TNF-β receptor, was discontinued in April 2005 during Phase III clinical trials for moderate to severe psoriasis after two patients developed sepsis.
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Pharmacokinetics
Etanercept has a mean half-life of approximately 4.3 days (70-100 hours) and reaches peak concentration at approximately 48 to 60 hours with an absolute bioavailability of 58%. 19 Of the currently marketed anti-TNF agents approved for psoriasis, etanercept exhibits the shortest half-life. Potential advantages incurred by the shorter half-life can include more rapid drug elimination in the setting of a serious adverse event including an infectious episode. No formal pharmacokinetics studies have been conducted to investigate the metabolism of etanercept. However, using radiolabelled etanercept in patients with acute renal and hepatic failure did not demonstrate abnormally increased serum etanercept concentrations. Therefore, no dosage adjustment is needed in the presence of renal and hepatic impairment. 20 There are no apparent age-or gender-related pharmacokinetic differences. However, in children aged 4 to 8 years, the clearance of etanercept may be slightly reduced though no dose adjustment is warranted. 19, 21, 22 Furthermore, no dose adjustment is needed when etanercept is co-administered with methotrexate, warfarin, or digoxin.
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Indications and dosing
In the United States, etanercept is indicated for the treatment of adult patients (18 years or older) with chronic moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. 9 The recommended induction dose of etanercept in the treatment of moderate-to-severe plaque psoriasis is 50 mg twice weekly for 3 months followed by a maintenance dosage of 50 mg weekly. 26 There are data to demonstrate once-weekly administration of etanercept 50 mg is as effi cacious and well tolerated as etanercept 25 mg biweekly providing a more convenient dosing regimen. 27 In Europe, etanercept is indicated for the treatment of adults with chronic moderate to severe plaque psoriasis who have failed to respond to, or who have a contraindication to, or who are intolerant to other systemic therapies or photochemotherapy including cyclosporine, methotrexate or PUVA. 28 It is also indicated in the treatment of active and progressive psoriatic arthritis in adults who have failed disease-modifying anti-rheumatic drug (DMARD) therapy. The European dermatology expert group recommends the same dosing regimen as the one used in the US for the treatment of plaque psoriasis. 29 
Monotherapy
Etanercept has been shown to be effective as monotherapy for moderate to severe plaque psoriasis with dose dependent efficacy. 26, [30] [31] [32] [33] [34] [35] [36] [37] [38] Published data from large randomized control trials conducted by various investigators from the Etanercept Psoriasis Study Group have found that at 12 weeks, 34% of patients receiving 25 mg of etanercept biweekly (biw) and 47% to 49% of patients receiving 50 mg biw, had improvement of PASI 75 from baseline compared with 3% to 4% of patients receiving placebo. [30] [31] [32] This response is dose dependent with faster and more signifi cant responses occurring in patients taking 50 mg biw. 30, 31 Papp et al 30 in their Phase III trial of 583 patients reported that by week 4, only the 50 mg biw group had a statistically signifi cant number of people (10%) achieving PASI 75, while the 25 mg biw group achieved statistical signifi cance at week 8. At week 12, the difference between the etanercept 50 mg biw group and the 25 mg biw group were statistically signifi cant with a greater response of 47% compared to 34% of patients with PASI 75, respectively. 30, 31 Clinical response may continue to improve or be maintained with sustained etanercept therapy. Evidence from the two large Phase III randomized-controlled trials (RCT) with 6 months follow-up of patients continuing treatment found that 44% to 45% of patients receiving 25 mg biw and 54% to 59% of patients receiving 50 mg biw achieved PASI-75. 30, 31 Sustained treatment up to 96 weeks in an openlabel extension of a large (n = 591) RCT showed that longterm etanercept 50 mg biw can maintain psoriasis response. 39 The percent of patients who achieved PASI 75 was 47% at 12 weeks, 60% at 24 weeks, 63% at 48 weeks, and 51% at 96 weeks.
There is evidence from Papp et al that decreasing the 50 mg biw dose to 25 mg biw at 12 weeks results in maintenance of benefi ts and even improved response in some patients. 30 They found that stepped down treatment from 50 mg to 25 mg biw after 12 weeks of treatment, resulted in 54% of patients with PASI-75 at 24 weeks compared to 45% of patients who had received 25 mg biw for 24 weeks. 77% of patients were able to maintain a PASI 75 score and 97% maintained a PASI score greater than 50% while on the reduced etanercept dose. Additionally, about one third of the 88 people who did not achieve a PASI 75 score at 12 weeks while taking 50 mg biw did at 24 weeks despite the decrease in dose. 30 These data suggest that most people may benefi t from the faster, more effective resolution at the higher dose of 50 mg biw, and will be able to maintain the benefi ts of etanercept induction dose while only taking 25 mg biw after the 12 weeks. In patients who do demonstrate loss of clinical response when transitioned from 50 mg to 25 mg BIW, ineffective dosing of patients with higher body mass index (BMI) may account for some of these cases. 40 In general, obese patients (BMI greater than 30) are poorer responders. Studies have shown that adipose tissue produces elevated levels of TNF-α. 41 Since patients that are obese have more adipose tissue than non-obese patients, it is believed that obese patients have elevated TNF-α levels and thus the etanercept dose is more often inadequate.
A recent study evaluated the use of etanercept in children and adolescents (4-17 years of age) with moderate to severe plaque psoriasis. Patients were dosed once weekly with 0.8 mg/kg of etanercept up to a maximum of 50 mg weekly. The percent of patients who achieved a PASI 75 response from baseline was 57% compared to 11% in those patients receiving placebo (p Ͻ 0.001).
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Combination therapy
The concept of maximizing effi cacy and minimizing adverse side effects through the combined use of topical, phototherapy, and systemic agents has been exercised extensively. Combination therapy is most useful to treat patients who have failed monotherapy and in the prevention of step-down deterioration. Treatment with prebiologic agents is limited to rotational therapy due to concerns of cumulative toxicity and major organ adverse side effects; the advent of biologic agents has increased feasibility of continuous therapy for long-term control, particularly in patients with recalcitrant disease. Additive immunosuppression may be a concern. For this reason, biologics including etanercept are not routinely used in combination with drugs such as cyclosporine.
Etanercept and topical corticosteroids
A consensus statement from the European dermatology expert group on the use of etanercept encourages the use of topical corticosteroids in combination with etanercept, particularly at the start of therapy to increase the speed of therapeutic response. 29 Combination of etanercept with phototherapy is of greater concern due to etanercept's immunosuppressive side effects and phototherapy's possible increased risk of skin cancers. Although there are no data on the concomitant use of etanercept and PUVA, this combination should only be used with caution in fair-skinned patients as the increased risk of skin cancers has been demonstrated in patients receiving cyclosporine who were previously treated with PUVA.
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Etanercept and narrowband ultraviolet light B (NBUVB)
A multicenter, open-label, single-arm prospective study (the Utilization of NB-UVB Light Therapy and Etanercept for the Treatment of Psoriasis [UNITE] study) evaluated the efficacy of etanercept 50 mg twice weekly in combination with NB-UVB 3 times weekly in patients with moderate to severe psoriasis (n = 86). 45 After 12 weeks, the percent of patients achieving a PASI 75 response was 84.4%. The percentage of patients who achieved a PASI 90 or PASI 100 response was 58.1% and 26%, respectively. In this study, the combination of etanercept and NB-UVB was effi cacious and generally well tolerated with no increase in photosensitivity noted. The addition of NB-UVB may serve as an option for the subset of patients who experience worsening of psoriasis after "stepping-down" from the induction dose. Caution should be used when starting etanercept for patients with known or suspected skin cancers due to case reports of squamous cell cancers (SCCs) that grew rapidly from pre-existing suspicious lesions after initiation of etanercept therapy. 46 
Etanercept and methotrexate
Most data involving the combination of etanercept with DMARDs, particularly, methotrexate are from rheumatology in the treatment of rheumatoid arthritis and psoriatic arthritis. The safety of this combination has been evaluated in rheumatoid arthritis in two large randomized, controlled, doubleblind clinical trials: the Trial of Etanercept and methotrexate with Radiographic Patient Outcomes (TEMPO) 47 (n = 682) and the Combination of Methotrexate and Etanercept in Active Early Rheumatoid Arthritis (COMET) 48 (n = 542). Each study found the combination of methotrexate and etanercept to be generally safe and well-tolerated with no statistically signifi cant increased rates and types of adverse events compared to the monotherapy groups.
Etanercept is approved for the treatment of both psoriasis and psoriatic arthritis. Clinical trials involving psoriatic arthritis allow concurrent use of systemic agents including methotrexate and prednisone. However, trials in psoriasis population often require that patients "wash out" from such medications, thus most available data on combination therapy are from case reports. [49] [50] [51] [52] Recently, Zachariae and colleagues 53 conducted a 24-week RCT evaluating combination therapy with etanercept and methotrexate in 59 patients with plaque psoriasis who had previously failed methotrexate monotherapy. Patients were randomized into two groups, one which received etanercept with methotrexate tapered up to week 4, and the other received etanercept combined with continued methotrexate treatment. In both arms, patients received etanercept 50 mg twice weekly for 12 weeks, and then 25 mg twice weekly for the remaining 12 weeks. The study reported a signifi cantly higher proportion of patients achieving a PGA of "clear" or "almost clear" and PASI 50, PASI 75, and PASI 90 at both 12 weeks and 24 weeks for combination treatment than etanercept/methotrexate taper. There was very little difference in adverse events in patients receiving combination therapy versus etanercept monotherapy. The combination of methotrexate with etanercept offers a promising option for patients suffering from psoriasis despite monotherapy with methotrexate or etanercept.
Etanercept and acitretin
There are few studies evaluating the effi cacy of acitretin with biologics. One case series described eight patients who had been treated with biologic agents and acitretin. 54 Five of the eight patients received treatment with etanercept (25-50 mg once to twice weekly) and acitretin (25-50 mg every other day to daily). One of these patients was later changed to adalimumab 40 mg weekly plus acitretin. Other than mild transient cholesterol elevation in one patient, there were no reported adverse effects.
A retrospective review (n = 15) described patients treated with acitretin and a biologic agent, four received etanercept. 45 The average time of treatment with both agents was 7.28 months. Overall, 29% of patients were clear of psoriasis, 43% showed 90% improvement, 14% showed 75% improvement, and 7.15% showed no change. One patient with a previous history of SCC continued to develop multiple SCCs while on etanercept therapy. After acitretin (25 mg every other day) was added, the rate of new SCC development decreased from an average of three SCCs diagnosed every two weeks to actinic keratosis with no new SCCs for 18 months. Another patient who was treated with acitretin and etanercept for 3 years developed non-Hodgkin's lymphoma, at which point etanercept was discontinued. The authors concluded that acitretin may be useful in combination with biologic agents, but further studies to determine the long-term safety and effi cacy were needed.
A randomized, investigator-blinded pilot trial treated 60 patients with either etanercept 25 mg twice weekly, acitretin 0.4 mg/kg daily, or etanercept 25 mg once weekly plus acitretin 0.4 mg/kg daily. 55 The PASI 75 response after 24 weeks was 45% in the etanercept group, 30% in the acitretin group and 44% in the combination group. No signifi cant differences in the mean value of liver enzymes, cholesterol, and triglycerides were reported in any of the three groups at all times investigated. The results from this study demonstrated that combination of acitretin and etanercept may serve as another long-term control option for psoriasis, or alternatively, etanercept could be added in patients inadequately treated with acitretin monotherapy. This combination greatly reduces the cost of treatment compared with etanercept 25 mg twice weekly while achieving similar effi cacy.
Toxicities and adverse reactions
Etanercept has been used worldwide in over half a million patients, with chronic conditions such as severe arthritis or psoriasis for more than 16 years. Etanercept has undergone numerous short-term safety analyses in rigorous clinical trials in rheumatoid arthritis, psoriatic arthritis, and psoriasis and long-term safety analyses in both controlled clinical trials and post-marketing surveillance. 10, 31, 56, 57 Despite this longterm and extensive human experience, to date, the FDA has not reported any serious adverse events based on evidencebased, Grade A criteria (ie, statistically slight increased risk when comparing large etanercept treated population vs placebo treated population involving subjects who are basically healthy and not a carrier of chronic infection such as tuberculosis [TB] or hepatitis).
Injection site reaction
The most common adverse effect of etanercept appears to be a mild, transient injection site reaction, generally occurring during initial administration lasting between 3 and 5 days. Approximately, 37% of patients will experience this side effect. Appropriate medication administration including rotation of sites should be discussed with patients at teaching session.
Infections
The next most common side effect is an increased risk of infections, particularly upper respiratory tract infections and cold-like illnesses. Patients may have increased susceptibility to infections by intracellular organisms including TB and listeria. However, there is no evidencebased data demonstrating increased TB reactivation in etanercept users compared to the general population unlike TNF-monoclonal antibodies. 33, 46, 47 Some studies demonstrate that TB reactivation in etanercept users has an increased risk of presenting as an atypical or disseminated infection. 58 In contrast to etanercept, adalimumab and infl iximab are monoclonal antibodies that bind to soluble and transmembrane TNF-α and may cause complementmediated cell lysis of macrophages and monocytes; therefore, they appear to interfere to a greater extent with the host granulomatous defense against intracellular organisms such as TB.
The FDA, in their post-marketing surveillance database has recently strengthened their black box warning on all TNF-antagonists for fungal infections, with a specifi c focus on histoplasmosis. Of the 240 reports of histoplasmosis in patients receiving TNF-antagonists submitted to the FDA, 17 cases were related to etanercept (7%), with the rest related to infl iximab (207 cases; 86%) and adalimumab (16 cases; 6.6%). Patients from the endemic Ohio and Mississippi River valley regions made up 80% of these cases. 59 Long-term follow up of etanercept therapy up to 96 weeks found that exposure-adjusted rates of noninfectious and infectious adverse events were similar between the treatment group at weeks 12 and 96, and between the treatment group and placebo. 39 
Hepatitis B
There have been case reports of hepatitis B virus (HBV) reactivation in patients who are chronic carriers while receiving etanercept. 9, 60 The incidence of HBV reactivation is higher in patients receiving concomitant immunosuppressive therapy. 9, 60 Currently, the safety or effi cacy of treating patients who are HBV carriers with anti-viral therapy in conjunction with TNF-α antagonists to prevent HBV reactivation is not known. Caution should be taken when etanercept is considered in patients who are carriers of HBV.
Hepatitis C
In contrast to its effects on HBV, there have been case reports of etanercept use in patients with concurrent hepatitis C virus infection without worsening of hepatitis or interfering with hepatitis treatment. 61 Etanercept is not indicated for the treatment of chronic HCV although there has been one phase II randomized controlled study evaluating etanercept use in patients with chronic HCV. Etanercept was given as an adjuvant to interferon and ribavirin in 50 patients with chronic HCV with reports of an increased virologic response at week 24 (etanercept 63% vs placebo 32%) and no statistically signifi cant differences in hematological adverse effects. 62 Furthermore, there have been case reports that etanercept may be a safe option for treating psoriatic arthritis and psoriasis in patients with concurrent chronic HCV infection. 63 
Others
Serious infections and sepsis, including fatalities, have been reported in patients undergoing etanercept therapy. 9 There is a greater risk of mortality in patients who become septic while receiving etanercept. 64, 65 Several of the serious infections have occurred in patients on concomitant immunosuppressive therapy that, in combination with their underlying disease, may predispose this patient population to infections. It is advised that etanercept should be discontinued until resolution of serious infection or sepsis. Further, serious adverse events such as demyelinating disease, congestive heart failure, hematological abnormalities, and systemic lupus-like condition are rare and primarily based on anecdotal evidence. 64, 65 Another consideration for patients treated with long-term TNF-α antagonists, including etanercept, is the possibility of increased weight gain. 66, 67 Additionally, etanercept antibodies may be encountered in up to 16% of patients; 68 however these antibodies are non-neutralizing and do not appear to effect effi cacy or safety profi les. 9 
Malignancy
The incidence of malignancy was investigated in the 96-week trial of etanercept 39 and compared to the incidence of cancer in the population. The authors found 9 malignancies during the open-label follow up and compared the incidence to national cancer databases. Observed numbers of total malignancies were not statistically signifi cantly different from the expected numbers of total malignancies based on National Cancer Institute data. 39 The FDA recently issued an Early Communication regarding the possible association between TNF blockers and the development of lymphoma and other malignancies in children and young adults. Over a 10-year interval, beginning in 1998 through 2008, there were approximately 30 reports of cancer occurring in children and young adults who began taking TNF inhibitors (along with other immunosuppressive medications such as methotrexate, azathioprine or 6-mecaptopurine), when they were aged 18 or less. Approximately half of the cancers reported were lymphoma. At the current time, the FDA believes that the potential benefi ts of TNF inhibitors outweigh the potential risks but further long-term studies are necessary to provide defi nitive answers about whether the use of TNF inhibitors in children increase the occurrence of cancers. 69 
Pregnancy
Etanercept and other TNF-α antagonists are considered category B drugs for pregnancy. Limited data are available on the safety of etanercept in pregnant or lactating patients. Because animal reproductive studies are not always predictive of human response, this drug should not be used in pregnancy unless clearly needed. It is not known whether etanercept is absorbed systemically after ingestion and so there is a potential for serious adverse reactions to the nursing infant. A decision should be made whether to discontinue etanercept before nursing. There is no evidence supporting embryo toxicity, teratogenicity or increased pregnancy loss. 70, 71 Currently, there are no studies describing the effect of etanercept on human lactation or the nursing infant. Thus, the use of etanercept during pregnancy and lactation is not recommended. Caution is advised when prescribing to women of reproductive age.
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Follow-up
A baseline and annual Mantoux test using purifi ed protein derivative (PPD) is required to monitor for TB. Although widely used, the PPD test has a number of limitations including lack of sensitivity in immunocompromised and active TB patients and lack of specifi city in bacille Calmette-Guérin (BCG)-exposed individuals. Two novel FDA approved assays for detecting latent TB can be considered. The QuantiFERON ® -TB Gold test (QFT-G; Cellestis Ltd, Carnegie, Australia) and T-Spot ® TB (Oxford Immunotec, Abingdon, UK) may offer greater sensitivity and specifi city than Mantoux test, especially in context of immunosuppression and previous BCG vaccination. 73 Preliminary studies using QFT-G in screening for TB in rheumatoid arthritis patients undergoing TNF-inhibitor therapy has suggested that it is sensitive for detecting latent TB in patients previously exposed to various immunosuppressive therapies at the time of the QFT-G testing. 74 Complete blood count and liver function tests may also be obtained at baseline with periodic monitoring. History and physical examination should be obtained while a patient is on this medication. Due to reports of hepatitis B reactivation, screening for hepatitis B and C should be considered in the appropriate clinical setting.
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